• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ingevity (NGVT) Just Gave Investors Something To Think About

    Simply Wall St·10/09/2026 05:37:51
    Listen to the news

    Ingevity (NGVT) has set a firm date for its next financial update. The company plans to release third quarter 2026 results after the market closes on November 4, followed by a webcast on November 5.

    Recent trading paints a mixed picture for Ingevity. The share price has a 1-month share price return of 3.3% and a year-to-date share price return of 18.8%. The 1-year total shareholder return of 32.2% and 3-year total shareholder return of 74.3% point to stronger longer-run momentum despite a softer 90-day share price return, setting the stage for investors to reassess expectations as the next earnings webcast approaches.

    Spot emerging momentum stories around Ingevity by scanning our hand-picked list of quality materials and chemicals stocks in the 27 high quality undervalued stocks.

    Ingevity has a complex set of businesses and a strong recent shareholder record, yet the valuation question sits in a different place. After this latest move, are you paying a fair price for that mix of assets and cash flows?

    Most Popular Narrative: 20% Undervalued

    The most followed valuation narrative for Ingevity pegs fair value at $89, above the last close of $71.41. This frames today’s debate around whether the recent share price strength has fully reflected that upside or still leaves room on the table.

    Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals supporting both revenue quality and sustained EBITDA margin improvement.

    See why 1 investors see Ingevity as 20% undervalued.

    Result: Fair Value of $89 (UNDERVALUED)

    Still, the Ingevity story can break if tariff pressure continues to weigh on Advanced Polymer Technologies profitability or if planned divestitures add more earnings volatility than clarity.

    Find out about the key risks to this Ingevity narrative.

    Another View: What Multiples Say About Ingevity

    The story on Ingevity shifts once you look at simple valuation ratios. The shares trade on a P/E of 97.4x, while the estimated fair ratio sits at 32.2x, and both the peer group on 26.2x and the wider US Chemicals sector on 22.1x are far lower.

    That gap suggests the market is already paying a heavy premium for NGVT compared with similar businesses and even relative to where the fair ratio implies pricing could move. If the narrative of a 20% undervaluation is right, how comfortable are you with paying over 3x the sector P/E for that possibility?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:NGVT P/E Ratio as at Oct 2026
    NYSE:NGVT P/E Ratio as at Oct 2026

    Next Steps

    Mixed signals like these often split opinion on Ingevity, so move quickly, review the numbers for yourself, and weigh up the 4 key rewards and 3 important warning signs.

    Looking for more Ingevity-sized investment ideas?

    Do not stop with Ingevity. Broaden your watchlist with a few focused screens that surface opportunities you might otherwise miss, especially as market stories keep shifting.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.